Premium
Serum miR‐221 serves as a biomarker for Parkinson's disease
Author(s) -
Ma Wenbin,
Li Yingying,
Wang Chao,
Xu Fan,
Wang Meiling,
Liu Yiming
Publication year - 2016
Publication title -
cell biochemistry and function
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.933
H-Index - 61
eISSN - 1099-0844
pISSN - 0263-6484
DOI - 10.1002/cbf.3224
Subject(s) - biomarker , parkinson's disease , disease , medicine , microrna , rating scale , stage (stratigraphy) , oncology , real time polymerase chain reaction , receiver operating characteristic , gastroenterology , biology , psychology , genetics , gene , paleontology , developmental psychology
Parkinson's disease (PD) is the common age‐related neurodegenerative disorder. Sensitive, noninvasive biomarkers that facilitate PD diagnosis and stage assignment are currently unavailable. This study aims to investigate the potential of 16 previous reported PD‐associated miRNAs as novel biomarkers for PD. The expression of 16 serum miRNAs was measured by quantitative reverse transcriptase polymerase chain reaction in 138 PD patients and 112 control populations. Analyses were undertaken to assess the specificity and sensitivity of miRNAs to predict PD. In addition, the relationship between deregulated miRNAs and Part III of the United Parkinson's Disease Rating Scale (UPDRS‐III) and Part V of the UPDRS (UPDRS‐V; the modified Hoehn and Yahr staging of PD) in PD patients was also assessed. It was found that the serums miR‐29c, miR‐146a, miR‐214, and miR‐221 were significantly decreased in PD patients compared with healthy control populations. In addition, serum miR‐221 was positively correlated with UPDRS‐III ( r = .4702) and UPDRS‐V ( r = .4788) score in PD patients. Furthermore, the receiver operating characteristic result of serum miR‐221 for prediction of PD was 0.787. Our preliminary findings indicate that downregulated serum miR‐221 might be a potential biomarker for PD evaluation.